Minocycline, a common acne treatment, may slow down the onset of MS in people with Clinically Isolated Syndrome (CIS). Researchers at the University of Calgary have been looking for drugs that could help stop the conversion from CIS to full MS.
We’re proud to be co-funding the phase 3 trial to test if simvastatin could become a treatment for secondary progressive MS. This phase 3 trial will involve over 1000 people with secondary progressive MS. It begins in summer 2017 and will take six years to complete.
A second independent review into how Personal Independence Payment (PIP) is working was published today. Following a first review commissioned by the Government in 2014, this one makes further recommendations to improve how PIP is implemented.
Researchers have found a small molecule plays a key role in helping the brain to repair some damage common in MS. Mice with an MS-like condition that were treated with a synthetic piece of this molecule, called microRNA, experienced regrowth of the myelin coating around damaged nerves.
HSCT could have long-term benefits for some people with MS, according to the results of a large study that we co-funded. After five years, progression had stopped in just under half of the 239 people eligible for the treatment.
Disease modifying treatments (DMTs) may be able to reverse the symptoms caused by MS for some people with relapsing MS, according to new research published in the Journal of Neurology. This is the first study that has measured whether people’s long-term symptoms improve following treatment.
New research has shown aggressive autologous haematopoietic stem cell transplantation (AHSCT or HSCT) can halt relapses for people with highly active, relapsing MS This trial involved 24 people and used high intensity chemotherapy prior to stem cell transplantation, with the aim of completely eliminating and then resetting the immune system.
News in the of this week's budget announcement has been dominated by the Government’s plans to make cuts to Personal Independence Payment (PIP).
The MS Society has been consistently speaking out about the devastating impact these changes could have on people with MS, and now we're calling for this issue to be urgently debated in Parliament.